REN and neoplasm: Pharmacologic inhibition of the renin-angiotensin system (RAS) with the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) in patients with non-muscle-invasive BC can prolong the 3-year and 5-year recurrence-free survival, independently of other known prognostic factors, including tumor multiplicity and the absence of bacillus Calmette–Guérin instillation [8,9,10].